These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24145340)

  • 1. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.
    Cannon DM; Mehta MP; Adkison JB; Khuntia D; Traynor AM; Tomé WA; Chappell RJ; Tolakanahalli R; Mohindra P; Bentzen SM; Cannon GM
    J Clin Oncol; 2013 Dec; 31(34):4343-8. PubMed ID: 24145340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
    Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
    Haslett K; Bayman N; Franks K; Groom N; Harden SV; Harris C; Hanna G; Harrow S; Hatton M; McCloskey P; McDonald F; Ryder WD; Faivre-Finn C
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1341-1348. PubMed ID: 33232772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
    Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
    Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
    Jaksic N; Chajon E; Bellec J; Corre R; Ricordel C; de Latour B; Lena H; Schick U; de Crevoisier R; Castelli J
    Radiat Oncol; 2018 Aug; 13(1):147. PubMed ID: 30103774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
    Urbanic JJ; Wang X; Bogart JA; Stinchcombe TE; Hodgson L; Schild SE; Bazhenova L; Hahn O; Salgia R; Vokes EE
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):177-185. PubMed ID: 29487024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
    Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
    Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
    Gomez DR; Gillin M; Liao Z; Wei C; Lin SH; Swanick C; Alvarado T; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):665-70. PubMed ID: 23688815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.
    Kelsey CR; Das S; Gu L; Dunphy FR; Ready NE; Marks LB
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):997-1004. PubMed ID: 26581138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
    Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
    Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
    Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
    Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
    Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.